HMN 2026: What are the Origin cells for common malignant brain tumor in young adults

KAIST-Yonsei team identifies origin cells for malignant brain tumor common in young adults
GPCs serve as the cell of origin harboring the initial driver mutation in IDH-mutant gliomas. In patients with IDH-mutant glioma, GPCs (including OPCs) acquire the earliest IDH mutation and undergo progressive expansion. A subset of these mutated clones subsequently accumulates additional driver mutations, diverging into distinct molecular subtypes: 1p/19q codeletion drives the evolution toward oligodendroglioma, whereas ATRX and TP53 mutations promote astrocytoma development. In a mouse model, introduction of glioma-driver mutations into OPCs led to the formation of brain tumors after ~40 weeks, recapitulating the histopathological and molecular features of human IDH-mutant gliomas. Credit: Science (2026). DOI: 10.1126/science.adt0559

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50. It is a refractory brain cancer that is difficult to treat due to its high recurrence rate.

Until now, treatment has focused primarily on removing the visible tumor mass. However, a Korean research team has discovered for the first time that normal brain cells acquire the initial IDH mutation and spread out through the cortex long before a visible tumor mass harboring additional cancer mutations forms, opening a new path for early diagnosis and treatment to suppress recurrence.

Discovery of tumor origins in brain tissue

A joint research team led by Professor Jeong Ho Lee from the Graduate School of Medical Science and Engineering and Professor Seok-Gu Kang from the Department of Neurosurgery at Yonsei University Severance Hospital recently identified that IDH-mutant gliomas originate from glial progenitor cells (GPCs) present in normal brain tissue.

The findings are published in the journal Science.

Through precise analysis of tumor tissue obtained via extensive resection surgery and the surrounding normal cerebral cortex, the research team discovered that cells of origin harboring the IDH mutation already existed within brain tissue that appeared normal to the naked eye.

This result proves for the first time that malignant brain tumors do not emerge suddenly at a specific point in time, but rather begin within a normal brain and progress slowly over a long period.

The research team then used spatial transcriptomics—a cutting-edge analysis technology that shows which genes are operating where simultaneously—to confirm that these origin cells with mutations were indeed GPCs located in the cerebral cortex. Furthermore, they successfully reproduced the process of brain tumor development in an animal model by introducing the same genetic driver mutation found in patients into the GPCs of mice.

Comparison with previous brain tumor research

This study is a significant expansion of previous research identifying the origin of IDH wildtype malignant brain tumors. In 2018, the joint research team led a paradigm shift in brain tumor research by revealing that IDH wildtype glioblastoma, a representative malignant brain tumor, originates not from the tumor body itself, but from neural stem cells in the subventricular zone—the source of new brain cells in the adult brain.

The current study clarifies that even though IDH wildtype glioblastoma and IDH-mutant glioma are both types of brain cancer, their starting cells and points of origin are entirely different, proving that different types of brain tumors have fundamentally different developmental processes.

Implications for diagnosis and treatment

Professor Seok-Gu Kang (co-corresponding author) stated, “Brain tumors may not start exactly where the tumor mass is visible. A target approach focused on the origin cells and the site of origin according to the brain tumor subtype will serve as a crucial clue to changing the paradigm of early diagnosis and recurrence suppression treatment.”

Based on these research results, Sovagen Co., Ltd, a faculty startup from KAIST, is developing an innovative RNA-based drug to suppress the evolution and recurrence of IDH-mutant malignant brain tumors. Additionally, Severance Hospital is pursuing the development of technologies to detect and control early mutant cells in refractory brain tumors through the Korea-US Innovative Result Creation R&D project.

Dr. Jung Won Park (postdoctoral researcher at KAIST Graduate School of Medical Science and Engineering), a neurosurgeon and the sole first author of the study, said, “This achievement was made possible by combining KAIST’s world-class basic science research capabilities with the clinical expertise of Yonsei Severance Hospital. The question I kept asking while treating patients—”Where does this tumor originate?”—was the starting point of this research.”

Publication details

Jung Won Park et al, IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation, Science (2026). DOI: 10.1126/science.adt0559

Journal information:
Science


Key medical concepts

Spatial Transcriptomics

Clinical categories

OncologyNeurology


The content is provided for information purposes only.